Laxmi Dental Quarterly Results for Trading Insights
In Mar 2026, Laxmi Dental (LAXMIDENTL) reported revenue ₹75 Cr and net profit ₹10 Cr — revenue +19.0% YoY. Browse LAXMIDENTL complete financial statements for revenue, profit, balance sheet and cash flow data.
LAXMIDENTL Quarterly Results — Revenue, Profit & EPS Highlights
Laxmi Dental latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit LAXMIDENTL screener.
- Revenue of ₹75 Cr in Mar 2026 (+0.0% vs Jun 2026, +19.0% vs Mar 2025)
- Net Profit of ₹10 Cr in Mar 2026 (+0.0% vs Jun 2026, +150.0% vs Mar 2025)
- EBITDA of ₹14 Cr in Mar 2026 (-6.7% vs Jun 2026)
- Operating Margin of 16.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹1.83 in Mar 2026 (-2.1% vs Jun 2026)
Laxmi Dental Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LAXMIDENTL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 75 | 75 | 73 | 63 | 66 | - | 19.0% |
| Net Profit (₹ Cr) | 10 | 10 | 9 | 4 | 8 | - | - |
| EBITDA (₹ Cr) | 14 | 15 | 12 | 11 | 12 | - | - |
| EPS (₹) | 1.83 | 1.87 | 1.59 | 0.79 | 1.53 | - | - |
| Operating Margin (%) | 16.0% | 17.0% | 14.0% | 15.0% | 17.0% | - | - |
LAXMIDENTL Share Price Trend — 1-Year Movement Across Quarterly Results
Laxmi Dental 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Laxmi Dental share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
LAXMIDENTL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Laxmi Dental latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1900.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.1 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8560.0 | 2,986 | 751 | -5.0% | - | 25.2% | 302.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5013.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 435.5 |
|
Cipla
Mar 2026 |
₹114,875.60 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1104.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 87.3 |
All amounts in ₹ Crores